Clinical Trial Update: SB-715992 in Treating Patients With Metastatic Prostate Cancer That Did Not Respond to Docetaxel or Paclitaxel [Phase 2]

View source ↗

Summary

A Phase 2 trial evaluating SB-715992 in metastatic prostate cancer that progressed after docetaxel or paclitaxel has completed.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Prostate Cancer

Drugs mentioned

• SB-715992

Snippet

Sponsor: National Cancer Institute (NCI) | Conditions: Adenocarcinoma of the Prostate, Recurrent Prostate Cancer | Phase 2 | Status: COMPLETED